MX2023005696A - Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. - Google Patents

Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.

Info

Publication number
MX2023005696A
MX2023005696A MX2023005696A MX2023005696A MX2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A MX 2023005696 A MX2023005696 A MX 2023005696A
Authority
MX
Mexico
Prior art keywords
rna
preparing
storing
methods
same
Prior art date
Application number
MX2023005696A
Other languages
English (en)
Inventor
Ugur Sahin
Ramin Darvari
Steffen Panzner
Kaushik Thanki
Bakul Subodh Bhatnagar
Sumit Luthra
Jorrit- Jan Krijger
Serguei Tchessalov
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/059460 external-priority patent/WO2022218503A1/en
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2023005696A publication Critical patent/MX2023005696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere en general al campo de las composiciones de nanopartículas lipídicas (LNP) que comprenden ARN, a métodos para preparar y almacenar tales composiciones y al uso de tales composiciones en terapia.
MX2023005696A 2020-11-16 2021-11-15 Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. MX2023005696A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063114478P 2020-11-16 2020-11-16
US202063115128P 2020-11-18 2020-11-18
US202063115588P 2020-11-18 2020-11-18
EP2020082602 2020-11-18
US202163135723P 2021-01-10 2021-01-10
US202163149372P 2021-02-15 2021-02-15
PCT/EP2021/059460 WO2022218503A1 (en) 2021-04-12 2021-04-12 Lnp compositions comprising rna and methods for preparing, storing and using the same
PCT/EP2021/081675 WO2022101470A1 (en) 2020-11-16 2021-11-15 Lnp compositions comprising rna and methods for preparing, storing and using the same

Publications (1)

Publication Number Publication Date
MX2023005696A true MX2023005696A (es) 2023-05-29

Family

ID=78621901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005696A MX2023005696A (es) 2020-11-16 2021-11-15 Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.

Country Status (10)

Country Link
US (1) US20230414747A1 (es)
EP (1) EP4243788A1 (es)
JP (1) JP2023549266A (es)
KR (1) KR20230121752A (es)
AU (1) AU2021379090A1 (es)
CA (1) CA3198742A1 (es)
IL (1) IL302771A (es)
MX (1) MX2023005696A (es)
TW (1) TW202237148A (es)
WO (1) WO2022101470A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096858A1 (en) * 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
PL3368507T3 (pl) * 2015-10-28 2023-03-27 Acuitas Therapeutics Inc. Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych
ES2900272T3 (es) 2016-04-22 2022-03-16 BioNTech SE Métodos para proporcionar ARN monocatenario
WO2017218704A1 (en) * 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
CN113039174B (zh) * 2018-10-02 2023-11-17 英特利亚治疗股份有限公司 可电离的胺脂质
KR20220133224A (ko) * 2020-01-28 2022-10-04 모더나티엑스, 인크. 코로나바이러스 rna 백신
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium

Also Published As

Publication number Publication date
JP2023549266A (ja) 2023-11-22
US20230414747A1 (en) 2023-12-28
EP4243788A1 (en) 2023-09-20
KR20230121752A (ko) 2023-08-21
IL302771A (en) 2023-07-01
CA3198742A1 (en) 2022-05-19
TW202237148A (zh) 2022-10-01
AU2021379090A1 (en) 2023-06-15
WO2022101470A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MX2021009245A (es) Metodos de preparacion de nanoparticulas lipidicas.
MX2022009280A (es) Vacunas de arn contra el coronavirus.
PH12021550701A1 (en) Ionizable amine lipids
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
MX2020003413A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
ZA202002094B (en) Trispecific proteins and methods of use
TN2019000039A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12021551279A1 (en) Modified amine lipids
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
NZ631112A (en) Crystalline bromodomain inhibitors
MY143795A (en) Tetrahydropyridoindole derivatives
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
AU2021410666A9 (en) Nanomaterials comprising ester-linked acetals
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2021012138A (es) Preparacion y almacenamiento de formulaciones de arn liposomico adecuadas para terapia.
GEP20247585B (en) Furoindazole derivatives
MX2022001933A (es) Inhibidores de enzimas.
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
ZA202208541B (en) Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
MX2022002069A (es) Inhibidores de enzimas.